RxDoctor Payments Data

Jeffery Greski, DO

Urology · Rochester Hills, MINPI 1073619441

Payments from drug & device makers

$5,708in general payments, 2019–2025

Across 277 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$847
  • Sumitomo Pharma America, Inc.$695
  • Axonics, Inc.$372
  • Medtronic$332
  • Merck$267
  • AbbVie$236
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$5,685100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,708 in reported general payments places this provider in the 65th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$186,220
Medicare patients
589
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron14$16,193
XyostedTestosterone Enanthate23$14,129
MyrbetriqMirabegron16$7,070
Tamsulosin Hcl253$4,874
Dutasteride118$4,428
Methenamine Hippurate25$2,332
Finasteride97$1,676
Testosterone Cypionate40$1,299
Tolterodine Tartrate ErTolterodine Tartrate11$1,186
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst128$1,006
Oxybutynin Chloride ErOxybutynin Chloride21$692
NitrofurantoinNitrofurantoin Macrocrystal18$651
Cephalexin104$636
Alfuzosin Hcl ErAlfuzosin Hcl14$434
Testosterone13$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$695$16,19314 claims
Antares Pharma, Inc.Xyosted$193$14,12923 claims
Astellas Pharma US IncMyrbetriq$847$7,07016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 400 urology providers in Michigan.

Other urology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →